Adjunctive vitamin A and vitamin D3 (Cholecalciferol) supplement in allergic rhinitis with allergen-specific immunotherapy, A randomized, double blind, placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220228004

Enrollment

Registered

2022-02-28

Start date

2021-02-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis Allergic rhinitis, Allergen specific Immunotherapy, Vitamin D supplement, Vitamin A supplement, Dysfunctional regulatory T cell

Interventions

Vitamin A 25000 IU per week plus Vitamin D 50000 IU per week total 20 weeks,Vitamin D 50000 IU per week plus placebo 1 tab per week total 20 weeks,placebo 2 tabs per week total 20 weeks

Experimental Dietary Supplement,Experimental Dietary Supplement,Placebo Comparator Dietary Supplement

Vitamin A plus Vitamin D,Vitamin D plus placebo,Placebo

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 20-60 years with house dust mites allergic rhinitis

Exclusion criteria

Exclusion criteria: Previous AIT Previous Vitamin A and Vitamin D supplement Pregnancy/Breastfeeding Comorbidities: Heart/Kidney/Liver disease, malignancy, autoimmune disease

Design outcomes

Primary

Measure	Time frame
Symptoms score At week 10 and 20 Description	—

Secondary

Measure	Time frame
Dysfunctional T reg At week 10 and 20 Flow cytometry,Specific IgE and IgG4 At week 10 and 20 ELISA	—

Countries

Thailand

Contacts

Public ContactSopit Siriwongmongkol

Phramongkutklao hospital

Piggy_oozzy@hotmail.com0858665990

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026